Quantcast

Latest insulin pump Stories

2011-06-27 06:00:00

SAN MATEO, Calif., June 27, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed dosing the first patient in Part B of the ongoing Phase I study. Part B involves dosing cenderitide with Medtronic's insulin pump technology. The trial is being conducted pursuant to Nile's previously announced collaboration with Medtronic and is the first clinical step towards...

2011-06-24 16:01:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced final results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog®, reduces the variability of insulin absorption and reduces post-meal glycemic excursions compared to NovoLog alone. Halozyme is...

2011-06-24 16:00:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced data from a new analysis characterizing the effects of SYMLIN® (pramlintide acetate) injection in patients with type 1 diabetes who used insulin pumps during two previously completed clinical studies. The data, which will be presented during a poster presentation at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, demonstrated that...

2011-06-08 07:00:00

INDIANAPOLIS, June 8, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental new drug application (sNDA) with the following updates to the Humalog label: continuous insulin infusion pump therapy in children 4 years of age and over with type 1 diabetes extension of the time-in-use in the external pump reservoir to a maximum of seven days; and extension of the time-in-use of the infusion...

2011-06-06 19:58:18

Rensselaer Polytechnic Institute Researchers Play Key Role in Development of "Closed Loop" Artificial Pancreas Engineering researchers at Rensselaer Polytechnic Institute are combining automation techniques from oil refining and other diverse areas to help create a closed-loop artificial pancreas. The device will automatically monitor blood sugar levels and administer insulin to patients with Type 1 diabetes, and aims to remove much of the guesswork for those living with the chronic disease....

2011-06-02 03:00:00

WEST CHESTER, Pa., June 2, 2011 - Animas Corporation announced today the receipt of CE Mark approval for Animas® Vibe(TM), the first and only continuous glucose monitoring (CGM)-enabled insulin pump system with Dexcom G4(TM) CGM technology. Animas® Vibe(TM) brings together the unique features of an Animas® insulin pump and the convenience of Dexcom CGM, which is the only sensor approved for up to seven days of wear. To view the...

2011-06-02 00:00:32

The website's new Carb Planning Tool helps people with diabetes estimate their carbohydrate intake, while its new Diabetes Product Directory allows users to learn about currently available diabetes products in numerous categories, plus read user reviews and even rate the products themselves. Mount Laurel, NJ (PRWEB) June 01, 2011 DiabetesCare.net, the fastest growing, advertising-free diabetes resource on the Internet, has launched its latest free-to-use resources for people with diabetes:...

2011-05-17 07:45:00

SUNNYVALE, Calif., May 17, 2011 /PRNewswire/ -- Asante Solutions, Inc. (Asante), a medical device company focused on diabetes care, announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the company's Pearl Insulin Pump. Last month, the Pearl also received the CE Mark, a European proof of conformity that certifies the product meets EU safety, health and environmental requirements. "We are pleased to accomplish these important regulatory milestones, and we are...

2011-05-11 08:00:00

WEST CHESTER, Pa., May 11, 2011 /PRNewswire/ -- Animas Corporation and LifeScan, Inc., both members of the Johnson & Johnson Family of Diabetes Companies, today announced plans to further build upon their existing collaborative efforts to co-develop and market innovative new products and tools for people living with diabetes. The increased collaboration also will include more closely aligning their commercial organizations to actively co-promote their product offerings, such as the...

2011-05-10 07:00:00

NEW YORK and SAN DIEGO, May 10, 2011 /PRNewswire/ -- The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that they have entered into a research collaboration agreement to provide financial support for a series of clinical studies to investigate the feasibility of mixing pramlintide, an analog of the human hormone amylin, with insulin to treat type 1 diabetes. Pramlintide, marketed by Amylin as SYMLIN®...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related